TY - JOUR
T1 - Spotlight on ixazomib
T2 - Potential in the treatment of multiple myeloma
AU - Muz, Barbara
AU - Ghazarian, Rachel Nicole
AU - Ou, Monica
AU - Luderer, Micah John
AU - Kusdono, Hubert Daniel
AU - Azab, Abdel Kareem
N1 - Publisher Copyright:
© 2016 Muz et al.
PY - 2016/1/11
Y1 - 2016/1/11
N2 - Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the first oral PI approved by US Food and Drug Administration. This review discusses the biochemical properties, mechanisms of action, preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration approval of ixazomib.
AB - Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the first oral PI approved by US Food and Drug Administration. This review discusses the biochemical properties, mechanisms of action, preclinical efficacy, and clinical trial results leading to the US Food and Drug Administration approval of ixazomib.
KW - Biological mechanism
KW - Clinical trials
KW - Oral administration
KW - Proteasome inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84955111669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955111669&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S93602
DO - 10.2147/DDDT.S93602
M3 - Review article
C2 - 26811670
AN - SCOPUS:84955111669
SN - 1177-8881
VL - 10
SP - 217
EP - 226
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
ER -